tbuckley/cabot-search huggingface dataset:
Effect of Salicylate on Plasma Nonesterified Fatty Acids
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Directory of Approved Internships
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice.
Authors: J F Mandujano, N B D'Souza, S Nelson, W R Summer, R C Beckerman, J E Shellito
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

We hypothesized that therapy with granulocyte-macrophage colony stimulating factor (GM-CSF) would decrease intensity of murine Pneumocystis carinii pneumonia by upregulating alveolar macrophage function. Mice were depleted of CD4+ T lymphocytes and then inoculated intratracheally with P. carinii. Four weeks later, they received recombinant murine GM-CSF (rmGM-CSF) 5 micrograms/d subcutaneously for 7 and 14 d. At the end of therapy lung tissue was scored for intensity of P. carinii infection by silver methenamine stain and for inflammation by hematoxylin-eosin stain. We found that rmGM-CSF therapy significant decreased the intensity scores of PCP infection in comparison to control mice (1.88 +/- 0.47 vs 3.06 +/- 0.12, p < 0.001). Inflammation scores were not significantly different in the rmGM-CSF group compared with the control group (1.83 +/- 0.47 vs 2.83 +/- 0.67). Alveolar macrophages from mice treated with rmGM-CSF released significantly more tumor necrosis factor-alpha (TNF-alpha) than cells from control mice after in vitro stimulation with lipopolysaccharide (LPS) alone (2.65 +/- 0.30 vs 1.45 +/- 0.26 ng/ml, p = 0.01) or with LPS plus murine recombinant interferon-gamma (4.16 +/- 0.51 vs 2.25 +/- 0.34 ng/ml, p = 0.01). We conclude that GM-CSF therapy reduces the intensity of PCP and this effect is associated with an enhanced alveolar macrophage TNF-alpha production.
VENTILATION AND HEALTH
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Colonoscopy, tumors
Authors: M. Kaminski, J. Regula
Journal: Endoscopy (2013)

Endoscopy Essentials Reviews in the Endoscopy Essentials series cite publications from the past year which, in the authors’ opinion, reflect the state-of-the-art in endoscopy. Alongside a short summary of each paper, authors explain why they consider their selected articles to be of importance.
Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer.
Authors: Julie R. Nangia, Tao Wang, Mari Rude, Cynthia R. C. Osborne, Steven W. Papish, Jame Abraham, Frankie Ann Holmes, Michael A. Savin, Richard Paxman, Susan G. Hilsenbeck, C. Kent Osborne, Mothaffar F. Rimawi
Journal: Journal of Clinical Oncology (2016)

TPS10144 Background: Adjuvant chemotherapy treats micro-metastatic disease and decreases the risk of breast cancer recurrence. However, it may be associated with distressing side effects, including alopecia. Women with breast cancer rate chemotherapy-induced alopecia as one of the most severe, troublesome, and distressing side effects of chemotherapy. In many countries, scalp cooling has been introduced to prevent or reduce chemotherapy-induced alopecia. The theory is that scalp cooling causes cutaneous vasoconstriction, which reduces blood flow to the hair follicles during peak plasma concentrations of the chemotherapeutic agents and therefore reduces cellular uptake of these agents. It also results in reduced biochemical activity, which makes hair follicles less susceptible to the damage of the chemotherapy agents. Historically, success rates have been variable, but based on non-randomized studies, scalp cooling appears to be effective in preventing chemotherapy-induced alopecia especially in more recent studies. Methods: We are conducting a multi-center randomized non-blinded controlled prospective trial to evaluate the safety and efficacy of the Orbis Paxman Hair Loss Prevention System in reducing the incidence of chemotherapy-induced alopecia. Women with stage I-II breast cancer who will receive neoadjuvant or adjuvant anthracycline- or taxane-based chemotherapy, for at least four cycles are eligible. Participants are randomized in a 2:1 ratio to scalp-cooling or no cooling. Scalp-cooling is done using the Orbis Paxman Hair Loss Prevention System prior to, during and after each chemotherapy administration. The primary efficacy endpoints are hair preservation, defined as CTCAE v4 alopecia < 2, and device safety. Two hundred and thirty five (235) patients will be enrolled which will provide 85% power to detect a 20% difference in hair preservation, 15% in control group and 35% in scalp-cooling group . Secondary endpoints include: wig/scarf use and quality of life assessed by the EORTC QLQ-30, HADS and BIS. Study participants will be followed for 5 years post-study for time to first recurrence, overall survival, site of first recurrence, and incidence of isolated scalp metastasis. Clinical trial information: NCT01986140.
CORRESPONDENCE
Authors: F. A. E. Silcock
Journal: British Journal of Dermatology (1943)

Journal Article CORRESPONDENCE Get access F. A. E. Silcock F. A. E. Silcock 119, London Road, Leicester Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 55, Issue 5, 1 May 1943, Page 133, https://doi.org/10.1111/j.1365-2133.1943.tb10764.x Published: 01 May 1943
Conference on Metastasis: Clinical and Experimental
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Conference on Metastasis: Clinical and Experimental Get access JNCI: Journal of the National Cancer Institute, Volume 63, Issue 3, September 1979, Page 876, https://doi.org/10.1093/jnci/63.3.876-a Published: 01 September 1979
Relative Source Contributions of Diet and Air to Ingested Asbestos Exposure
Authors: James N. Rowe
Journal: Environmental Health Perspectives (1983)

Reliable assessments of the relative contributions of diet (food, beverages, and orally administered drugs) and air (inhaled fibers) to total ingested asbestos exposure are not feasible due to the paucity of quantitative data on the subject. Instead, scenarios for both modes of exposure were developed from the limited information available to give crude estimates of ingestion of asbestos from these routes. They suggest that such sources are potentially significant relative to the contribution of asbestos exposure derived from drinking water. Research recommendations are discussed.
JAMA 100 Years Ago
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aminophylline treatment in severe, acute asthma. A meta-analysis
Authors: B. Littenberg
Journal: JAMA (1988)

Aminophylline is routinely recommended as a basic part of the emergency treatment of asthma. A comprehensive search found 13 reports of controlled trials of intravenous aminophylline therapy in severe, acute asthma. These studies compared aminophylline therapy with treatment with either albuterol (salbutamol), epinephrine, or other bronchodilators. The 13 reports did not agree. Seven reported no difference in spirometric values between aminophylline treatment and the control regimens. Three found aminophylline treatment superior. Three favored the control regimen. The results of the 13 trials were reanalyzed and pooled. Overall, there was no difference between the aminophylline-treated groups and the control groups. Sensitivity analysis suggests that aminophylline therapy is ineffective alone but may be more effective than single-drug therapy when combined with an injected β-agonist. Despite widespread practice, available trials do not provide adequate evidence to support or reject the use of aminophylline in the treatment of severe, acute asthma. (<i>JAMA</i>1988;259:1678-1684)
Therapy for sickle cell vaso-occlusive crises. Controlled clinical trials and cooperative study of intravenously administered alkali. Cooperative urea trials group
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatology Highlights
Authors: Arslan Talat, Pir A. Shah, Daryl T.Y. Lau, Nicholas W. Russo, Robert S. Brown, Muhammad Amir, Preeti Reshamwala, Brett Fortune, Nidhi Jalan‐Sakrikar, Robert E. Schwartz
Journal: Hepatology (2020)

Talat, Arslan; Shah, Pir A.; Lau, Daryl T.Y.; Russo, Nicholas W.; Brown, Robert S. Jr.; Amir, Muhammad; Reshamwala, Preeti; Fortune, Brett; Jalan‐Sakrikar, Nidhi; Schwartz, Robert E. Author Information
CONTRACT PRACTICE AND ETHICS.
Journal: JAMA (1883)

Rising Fawn, Ga., Sept. 27, 1883. Prof. N. S. Davis, Chicago, Ill.: <h3>Dear Sir:</h3> In the editorial department of theJournal of the American Medical Association, of September 1st, is an article, " Contract Practice and Ethics." After reading that article I felt myself to be in a peculiar position. In the first place, I have always been, so far as I was aware, a staunch advocate of the established code, and opposed to all innovations or attempted changes for the purpose of increasing patronage. Now, from the reply to the query of J. P. W., and your comments, I find that so long as a physician is under a contract to do ordinary medical practice for a corporation, just so long he is debarred the privileges of a member of the American Medical Association. Now, in self defense allow some plea for the system. I am one of the barred
SURGERY OF NONHYPERPLASTIC OVARIAN CYSTS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Continuing Medical Education
Authors: Merilyn Wiler
Journal: JAMA (1977)

<h3>To the Editor.—</h3> In the article "Stop the Continuing Education Bandwagon" (237:2518, 1977), Daniel M. Baer, MD, stated, "It appears [in continuing education] that a formalized structure is being developed that is constraining rather than stimulating the pursuit of knowledge." He further stated, "A system of recognition, certification, and accreditation is being established that stresses traditionally oriented organized programs and fails to recognize the needs, objectives, initiative, and responsibility of the individual in planning and seeking his own continuing education." There is a group in Denver that recognized the need for continuing education 13 years ago and has been striving to fulfill that need using a formalized structure. What began as a tutorial in-service program set up at the request of medical technologists from several Denver hospitals grew because of popular demand so that in 1976-1977 there were 102 different courses, varying from two-hour evening sessions to four-day workshops, presented
Effect of Red Cell Factors on the Relative Viscosity of Whole Blood
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The incidence of exposure to needle sticks during surgery
Authors: J. W. Pate
Journal: JAMA (1990)

<h3>To the Editor.—</h3> The continuing debate in regard to the magnitude of risks to health care workers involved in treating patients with acquired immunodeficiency syndrome frequently generates dogmatic opinions unsupported by fact. Drs Ratzan and Schneiderman<sup>1</sup>say the following: No needle-stick data support the suggestion that any physician anywhere is likely to stick oneself 5 to 10 times per year. This is not only an unverifiable assumption in the literature, it is a priori preposterous. Such a physician belongs in a different, safer profession, where the practitioners use their feet, not their hands. In an ongoing prospective study of glove use and surgical team injuries during heart surgery using cardiopulmonary bypass, we have noted a mean of about 0.4 exposures of surgeons, scrub nurses, or other team members per operation. Exposures are defined as (1) needle, wire, or bone punctures of gloves with visible bleeding, scratch, or laceration
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC).
Authors: Neeraj Agarwal, Kenneth M. Boucher, Benjamin Maughan, Syed A. Hussain, Donald S. Kaufman, Vito Lorusso, Malcolm J. Moore, Matt D. Galsky, Guru Sonpavde
Journal: Journal of Clinical Oncology (2012)

308 Background: Weekly gemcitabine with day 1 cisplatin 70 mg/m 2 every 3-4 weeks (GC) is considered a conventional first line chemotherapy for advanced UC. Weekly split-dose cisplatin (delivering a similar cumulative dose per cycle) with concurrent weekly gemcitabine (wGC) may be less toxic and have similar activity, but has not been compared with GC. We pooled published phase II trials of GC and wGC to compare efficacy and safety. Methods: Two trials of wGC (n=74) patients and 3 trials of GC (n=131) were identified. A Cr Cl ≥60 ml/minute was required, except one trial of wGC that enrolled 19 patients with Cr Cl 40-60 ml/minute. Since the data were not derived from randomized trials, GC and wGC were not formally compared, and exact 95% quasi-binomial confidence intervals (CI), which allows for heterogeneity between studies in the same grouping, for response rates and grade ≥3 toxicities were calculated. Long-term outcomes were not uniformly reported and hence inevaluable. Results: The 95% CI overlapped, suggesting agreement between wGC and GC (Table). After accounting for random variability, no clear difference in the CR, PR, SD and grade ≥3 toxicities between GC and wGC were observed. Limitations of a retrospective study apply. Conclusions: GC and wGC yielded similar responses and grade ≥3 toxicities in advanced UC. These results are hypothesis-generating and in the absence of randomized trials, wGC should not be routinely substituted for GC in cisplatin-eligible patients. [Table: see text]
Workshop on the public health response to nasopharyngeal radium irradiation. From the Centers for Disease Control and Prevention
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dynamic of cytokine profiles predicts risk of HCC among HCV patients with advanced fibrosis after successful antiviral therapy
Authors: Ming-Lung Yu, Ming-Ying Lu, Shu-Chi Wang, Ming-Lun Yeh, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang
Journal: Journal of Hepatology (2020)